Dr. Gregory Michael Amend, MD

Dr. Amend practices at Mount Sinai Medical Center in Miami Beach, Florida, part of Mount Sinai Medical Center of Florida.

Dr. Amend's NPI, 1588076798, was assigned on May 22, 2014. Dr. Amend graduated from Renaissance School of Medicine at Stony Brook University in 2014. Dr. Amend holds New York license 308432.

Dr. Amend's primary practice is Mount Sinai Medical Center, at 4300 Alton Rd, Miami Beach, FL 33140 in Miami-Dade County. The practice phone is (305) 674-2121. Dr. Amend also practices at Mount Sinai Medical Center, 5 E 98th St, New York, NY 10029.

Dr. Amend's primary practice is Mount Sinai Medical Center in Miami Beach, Florida, part of Mount Sinai Medical Center of Florida. Dr. Amend is also affiliated with Mount Sinai West. The medical group on file is Mount Sinai Institute for Liver Medicine. Dmand AI also links Dr. Amend to 4 more hospitals, 4 medical groups, 2 group practices and clinics, 1 home health agency and 1 ambulatory surgery center, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Amend practices, 10 sites in all. Vendor and product names are available with a free account.

Urology is Dr. Amend's primary specialty in the NPI Registry, under taxonomy code 208800000X. Dr. Amend is board certified in urology by the American Board of Urology. Dmand AI has Dr. Amend's licenses on file in 3 states: New York, California and New Jersey.

Dmand AI lists bladder disease, enlarged prostate, enlarged prostate transurethral surgery (TURP), erectile dysfunction, kidney cysts, kidney removal surgery, prostate cancer and testicular dysfunction among the conditions Dr. Amend treats.

CMS data shows 432 Medicare services from Dr. Amend across 10 procedure codes in 2024, for 204 Medicare patients. Medicare paid $40,263 for them. Every service was in an office.

CMS counts 204 Medicare patients who saw Dr. Amend in 2024. The largest group is 65 to 74, with 75 patients. 75% of them have high cholesterol, and 74% have high blood pressure. 32% are also on Medicaid. Their average risk score is 2.34, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Amend's median patient age at 62, with 8% women.

In 2024, Dr. Amend wrote 719 Medicare Part D claims for 186 patients. 86% of them were for generic drugs. CMS names the drug for 622 of them, across 12 drugs with 11 or more claims each, at $77,320 in total drug cost. In 2023, CMS named 627 claims across 12 drugs.

Dr. Amend accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

Melanoma (skin cancer) excision: 1 to 10 procedures (CMS shows small counts as a range)

Prostate resection: 1 to 10 procedures (CMS shows small counts as a range)

Dmand AI links 32 papers to Dr. Amend, published from 2012 to 2024. 2021 was the busiest year, with 12. The most frequent topics are Sleep Apnea Syndromes, Urology and Monitoring, Physiologic. Dr. Amend has published most often in Urology. Dr. Amend's most frequent co-authors are Benjamin Newell Breyer, MD, Jordan Taylor Holler, MD and Michael Sadighian.

CMS Open Payments shows 238 general payments to Dr. Amend from 16 drug and device companies from 2016 to 2025. Compensation for serving as faculty or as a speaker for a medical education program make up the largest share, 46% of the total. Kerecis Limited paid the most, $67,739.

Dr. Amend graduated from Renaissance School of Medicine at Stony Brook University in 2014.

Dr. Amend is in network with 8 carriers, including Aetna, Blue Cross Blue Shield of Massachusetts and Cigna. Medicare plans come from the most carriers, 6. Check the plan with the practice before a visit.